Company Announcements

In August, the Sequenom Center for Molecular Medicine and CombiMatrix entered into a collaboration agreement to market chromosomal microarray analysis testing for prenatal testing.

In August, NanoString Technologies announced net proceeds of $47 million from its IPO (see IBO 6/30/13).

NanoString Technologies’ Prosigna Breast Cancer Prognostic Gene Signature Assay received FDA 510(k) clearance in September and is the company’s first FDA-clear IVD assay.

In August, Silicon Kinetics named Jay Smith CEO. He was previously COO at Plexera.

Reichert Life Sciences collaborated with Ridgeview Instruments to offer TraceDrawer molecular interaction data analysis software with its SR7000DC and SR7500DC surface plasmon resonance systems.

In September, PerkinElmer opened a training and demo lab for in vivo imaging technology at the Shanghai Medical College of Fudan University in China.

Product Introductions

MILabs introduced in June modular single photon emission computed tomography/PET/CT/MRI solutions offered through a partnership with MRI firm RS2D.

Affymetrix introduced the cost effective, high-throughput Axiom 384HT genotyping format, in which 384 samples are simultaneously processed with 384 discrete microarrays in a microplate format for analyzing up to 50,000 SNPs per sample. Content is customizable.

In July, Quanterix announced the commercial availability of its Simoa (single molecular array) technology, a digital form of ELISA utilizing paramagnetic beads in thousands of femtoliter-sized wells in arrays. Up to 10 different analyses can be tested in a single assay at a speed of 80 samples/hour.

Oxford Gene Technology released the CytoSure Consortium Cancer +SNP array (4 x 180k) for the simultaneous detection of CNV and loss of heterozygosity.

In August, Peptide Machines introduced the Discovery-4 four-vessel peptide synthesizer, which uses stock solutions and produces multiple peptides simultaneously on any scale from 0.05 mmol to 3.0 mmol per reactor.

Meso Scale Discovery released the V-PLEX biomarker tests, a line of validated immunoassays for clinical research for use with its SECTOR or QuickPlex instrument lines.

Forte Bio launched in September the Octet HTX system, the new flagship member of the Octet line of label-free interaction analysis systems. It features increased analysis speeds and sample throughput for kinetic analysis of up to 96 binding interactions simultaneously.

MR Solutions introduced a 3T MRI/SPECT scanner, in which the three gamma camera heads and focusing collimator are clipped onto the front of the bore of the MRI scanner.